Literature DB >> 6299712

Interactions of a monoclonal antibody to the insulin receptor with receptors for insulin-like growth factors.

R A Roth, B Maddux, K Y Wong, D M Styne, G Van Vliet, R E Humbel, I D Goldfine.   

Abstract

A monoclonal antibody to the human insulin receptor was tested for its ability to inhibit the binding of 125I-insulin-like growth factor I (IGF-I) and 125I-insulin-like growth factor II (IGF-II) to their receptors in human placenta membranes and cultured human IM-9 lymphocytes. In both placenta membranes and IM-9 cells, the antibody progressively inhibited the binding of 125I-IGF-I to its receptor with a potency that was 300-fold less than its ability to inhibit the binding of 125I-insulin to its own receptor. In contrast, in human placenta membranes, this antibody inhibited the binding of 125I-IGF-II to its receptor only slightly. These studies indicate, therefore, that this monoclonal antibody binds preferentially to the insulin receptor but also crossreacts to a lesser extent with the IGF-I receptor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6299712     DOI: 10.1210/endo-112-5-1865

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor.

Authors:  M A Soos; K Siddle; M D Baron; J M Heward; J P Luzio; J Bellatin; E S Lennox
Journal:  Biochem J       Date:  1986-04-01       Impact factor: 3.857

2.  Delineation of atypical insulin receptors from classical insulin and type I insulin-like growth factor receptors in human placenta.

Authors:  H A Jonas; A J Cox; L C Harrison
Journal:  Biochem J       Date:  1989-01-01       Impact factor: 3.857

3.  c-ras-Ha gene expression is regulated by insulin or insulinlike growth factor and by epidermal growth factor in murine fibroblasts.

Authors:  K H Lu; R A Levine; J Campisi
Journal:  Mol Cell Biol       Date:  1989-08       Impact factor: 4.272

4.  Dual regulation of glycogen metabolism by insulin and insulin-like growth factors in human hepatoma cells (HEP-G2). Analysis with an anti-receptor monoclonal antibody.

Authors:  E J Verspohl; R A Roth; R Vigneri; I D Goldfine
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

5.  Antireceptor antibodies as probes of insulinlike growth factor receptor structure.

Authors:  M Kasuga; N Sasaki; C R Kahn; S P Nissley; M M Rechler
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

6.  Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors.

Authors:  M A Soos; K Siddle
Journal:  Biochem J       Date:  1989-10-15       Impact factor: 3.857

7.  The receptor for insulin-like growth factor II mediates an insulin-like response.

Authors:  J Hari; S B Pierce; D O Morgan; V Sara; M C Smith; R A Roth
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

8.  Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo.

Authors:  Adam Doern; Xianjun Cao; Arlene Sereno; Christopher L Reyes; Angelina Altshuler; Flora Huang; Cathy Hession; Albert Flavier; Michael Favis; Hon Tran; Eric Ailor; Melissa Levesque; Tracey Murphy; Lisa Berquist; Susan Tamraz; Tracey Snipas; Ellen Garber; William S Shestowsky; Rachel Rennard; Christilyn P Graff; Xiufeng Wu; William Snyder; Lindsay Cole; David Gregson; Michael Shields; Steffan N Ho; Mitchell E Reff; Scott M Glaser; Jianying Dong; Stephen J Demarest; Kandasamy Hariharan
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.